Skip to content

Can exhausted T cells be revived? The PD-1 palaver

  • Chad Cipiti

By Richard Jefferys May 2007 Anyone who follows HIV research is familiar with how a new potential therapeutic target can suddenly appear in the scientific literature, generating much excitement and hype, only to subsequently shuffle quietly from the scene having…

Read more

Treatment Action Group Supports Maraviroc Approval

  • Chad Cipiti

May 1, 2007 Treatment Action Group (TAG) supports the approval of maraviroc for treatment of HIV infection in patients with prior antiretroviral experience. Maraviroc is an orally-available small molecule that binds to and alters the shape of CCR5, a cell…

Read more

Palm Project Interview Series: Barbara Shacklett

  • Chad Cipiti

February 8, 2007 About the Palm Project Interviews TAG has conducted a series of interviews with leading scientists about the underlying pathogenesis of AIDS to gain insights into emerging lines of research and observations about the current research funding environment.…

Read more

Palm Project Interview Series: Douglas Nixon

  • Chad Cipiti

February 8, 2007 About the Palm Project Interviews TAG has conducted a series of interviews with leading scientists about the underlying pathogenesis of AIDS to gain insights into emerging lines of research and observations about the current research funding environment.…

Read more

Palm Project Interview Series: Steven Deeks

  • Chad Cipiti

February 8, 2007 About the Palm Project Interviews TAG has conducted a series of interviews with leading scientists about the underlying pathogenesis of AIDS to gain insights into emerging lines of research and observations about the current research funding environment.…

Read more

2006 Pipeline Report

  • Chad Cipiti

What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Therapies in Clinical Trials By Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed Edited by Bob Huff August 2006 From the Forword: Twenty-five years into the global…

Read more

TMC114/r (darunavir/r, Prezista): Who’s Got the POWER?

  • Chad Cipiti

By Rob Camp May 25, 2006 Darunavir (DRV) is a ritonavir(r)-boosted protease inhibitor that has been studied for use in heavily treatment-experienced patients. In the future, DRV/r will be evaluated for use in less-experienced, treatment-naïve and pediatric populations. The current…

Read more

Civil Society Perspectives on TB/HIV

  • Chad Cipiti

Published 2006 This publication is cosponsored by the Open Society Institute, a private operating and grantmaking foundation whose aim is to shape public policy in order to promote democratic governance, human rights, and economic, legal, and social reform, and the…

Read more
Back To Top